Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Pancoronavirus Vaccine Cov-RBD-scNP-001 in Healthy Adults
NCT06950177Phase 1Terminated
- Sponsor
- Duke University
- Start
- Aug 2025
- Primary completion
- Sep 2026
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of Cov-RBD-scNP-001 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Duke University. Primary endpoints: Number of participants with solicited local and systemic reactogenicity events at Day 36, Number of participants with study vaccine-related and unrelated unsolicited non-serious adverse events at Day 57 and 2 more. Started Aug 2025; status: terminated.
02
Drugs
Cov-RBD-scNP-001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06950177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06950177.